Combined Effect of Continuous and Interval in Addition to Tadalafil Drug on Erectile Dysfunction

• Status: Recruiting
• Trial end date: 2021-03-30
• Target enrollment: 0
• Participant gender: Male

Summary

Erectile dysfunction (ED) is the persistent inability to attain and maintain a sufficient erection to permit satisfactory sexual performance. ED, a condition closely related to cardiovascular morbidity and mortality, is frequently associated with obesity. The importance of reducing cardiovascular risk factors remains fundamental to the overall vascular good health of the man, and that includes sexual vascular health. ED shares similar modifiable risks factors with coronary artery disease (CAD). Lifestyle modification that targets CAD risk factors may also lead to improvement in ED.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Tadalafil

Criteria

Inclusion Criteria:

1. Sixty sedentary obese married men with BMI > 30 kg/m2.

2. The age of participants will range from 40-50 years old.

3. Blood pressure will be < 140/90 mm Hg.

4. The patients who will have ED at least from 6 months with IIEF-5 score < 22.

Exclusion Criteria:

1. Alcoholic, smoker, hypertensive, diabetic, and addicted patients.

2. Patients with pulmonary, renal, hepatic, and cardiac disorders.

3. Lower limb arthritis or orthopaedic disorders that will hinder the training program.

4. Prostatic inflammation, hyperplasia, and tumors.

5. Participation in a structured sport program in the previous 6 months.

6. previous pelvic and genital surgeries.